Evidence mapPaperPMID 41953254Full record

ArticleJournal of clinical & translational endocrinology2026

A functional medicine approach to diabetes control and quality of life: an open-label randomized pilot study.

Mohamed Eldib, Betul Hatipoglu, Michelle Beidelschies, Marilyn Alejandro-Rodriguez, Huijun Xiao, Michael Rothberg, Mark Hyman, Keren Zhou

Abstract read
In one paragraph

Article in Journal of clinical & translational endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohamed EldibDepartment of Diabetes, Endocrinology and Metabolism, Cleveland Clinic, Cleveland, OH, USA.
Betul HatipogluDepartment of Medicine, Case Western Reserve University School of Medicine, Diabetes and Obesity Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Michelle BeidelschiesCenter for Functional Medicine, Cleveland Clinic, OH, USA.
Marilyn Alejandro-RodriguezDepartment of Community Health, Mercy Health, Lorain, OH, USA.
Huijun XiaoDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
Michael RothbergCenter for Value-Based Care Research, Cleveland Clinic, Cleveland, OH, USA.
Mark HymanFunction Health, Lenox, MA, USA.
Keren ZhouDepartment of Diabetes, Endocrinology and Metabolism, Cleveland Clinic, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There has been increasing public interest in a functional medicine (FM) approach to the care of type 2 diabetes (T2D). However, it is unclear if this approach can further improve diabetes management beyond conventional diabetes care. This study compared the addition of a FM approach (intensive lifestyle modifications and tailored dietary supplements) plus usual care (FM) to conventional endocrinology management alone (usual care, UC). Methods: In a 24-month unblinded randomized trial, participants with type 2 diabetes (T2D) were randomized to receive either FM or UC. The primary endpoint was discontinuation of insulin with no increase in HbA1c or HbA1c < 7% at 12 months. Secondary endpoints included changes in HbA1c, insulin dosage by weight, cardiometabolic biomarkers, hypoglycemic episodes, total number of medications and quality-of-life scores. Results: A total of 107 individuals were screened - 34 were randomized into FM and 37 into UC. Participants were 46% female and median age was 62 years. Median baseline HbA1c was 7.75%. Of those randomized, 47 participants completed the study (FM: 20; UC: 27); 15.8% of patients in FM arm achieved the primary endpoint compared to 11.1% in the UC arm (p = 0.68). Secondary exploratory endpoints including change in HbA1c, insulin dosage by weight, hypoglycemia, BMI, weight and quality-of-life did not differ significantly between arms. Conclusion: The addition of FM did not lead to significant improvement in glycemic, metabolic or quality-of-life outcomes compared to usual care for individuals with type 2 diabetes.

Indexed as

Functional medicineType 2 diabetes

Identifiers

PMID41953254
PMCPMC13054257

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.